Contemporary management of postchemotherapy testis cancer.

[1]  R. Huddart,et al.  Canadian consensus guidelines for the management of testicular germ cell cancer. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[2]  P. Albers,et al.  Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. , 2012, European urology.

[3]  A. Horwich,et al.  tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial , 2011 .

[4]  B. Carver,et al.  The role of lymphadenectomy for testicular cancer: indications, controversies, and complications. , 2011, The Urologic clinics of North America.

[5]  S. Daneshmand,et al.  The management of subcentimeter residual mass in NSGCT: pcRPLND vs. observation. , 2011, Urologic oncology.

[6]  A. Wein,et al.  Campbell-Walsh Urology , 2011 .

[7]  S. Fosså,et al.  Sequelae of treatment in long-term survivors of testis cancer. , 2011, European urology.

[8]  S. Daneshmand,et al.  Management of residual mass in nonseminomatous germ cell tumors following chemotherapy , 2011, Therapeutic advances in urology.

[9]  A. Horwich,et al.  EAU guidelines on testicular cancer: 2011 update. , 2011, European urology.

[10]  T. Powles,et al.  Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Duncan,et al.  Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  G. Pond,et al.  Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. , 2011, European urology.

[13]  P. Okunieff,et al.  Commentary Testicular Cancer Survivorship: Research Strategies and Recommendations , 2022 .

[14]  M. Gleave,et al.  Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  M. Bains,et al.  TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Einhorn,et al.  Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Daneshmand,et al.  Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Daneshmand,et al.  Resection of the inferior vena cava without reconstruction for urologic malignancies. , 2009, Urology.

[19]  P. Albers,et al.  Retroperitoneal lymph node dissection after chemotherapy , 2009, BJU international.

[20]  L. Schwartz,et al.  NCCN clinical practice guidelines in oncology: testicular cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[21]  B. Carver,et al.  Management of post-chemotherapy extra-retroperitoneal residual masses , 2009, World Journal of Urology.

[22]  E. Barret,et al.  Postchemotherapy laparoscopic retroperitoneal lymph node dissection in nonseminomatous germ-cell tumor. , 2009, Journal of endourology.

[23]  P. Warde,et al.  POST-CHEMOTHERAPHY RETROPERITONEAL LYMPH NODE DISSECTION FOR TESTICULAR GERM CELL TUMORS: IS SURGERY INDICATED IN ALL AND IS BILATERAL TEMPLATE NECESSARY? PRINCESS MARGARET HOSPITAL EXPERIENCE , 2009 .

[24]  S. Culine,et al.  Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. , 2009, The Journal of thoracic and cardiovascular surgery.

[25]  R. Motzer,et al.  Clinical outcome and predictors of survival in late relapse of germ cell tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Steyerberg,et al.  Re: Axel Heidenreich, David Thüer, Sergej Polyakov. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis. Eur Urol 2008;53:260-74. , 2008, European urology.

[27]  T. Christmas,et al.  Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome , 2008, BJU international.

[28]  D. Dearnaley,et al.  Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse , 2008, British Journal of Cancer.

[29]  S. Fosså,et al.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. , 2008, European urology.

[30]  R. Motzer,et al.  Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Louwman,et al.  Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. Einhorn,et al.  Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? , 2007, Cancer.

[33]  S. Perkins,et al.  High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. , 2007, The New England journal of medicine.

[34]  L. Einhorn,et al.  Post chemotherapy RPLND in patients with elevated markers: current concepts and clinical outcome. , 2007, The Urologic clinics of North America.

[35]  B. Carver,et al.  Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. , 2007, Urology.

[36]  P. Spiess,et al.  Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. , 2007, The Journal of urology.

[37]  Yvonne Vergouwe,et al.  Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients. , 2007, European urology.

[38]  S. Fosså,et al.  Late relapses of germ cell malignancies: incidence, management, and prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Sheinfeld,et al.  Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. , 2006, The Journal of urology.

[40]  L. Einhorn,et al.  Is retroperitoneal histology predictive of liver histology at concurrent post-chemotherapy retroperitoneal lymph node dissection and hepatic resection? , 2006, The Journal of urology.

[41]  S. Fosså,et al.  Late recurrences of germ cell malignancies: a population-based experience over three decades , 2006, British Journal of Cancer.

[42]  A. Horwich,et al.  Guidelines on testicular cancer. , 2005, European urology.

[43]  L. Einhorn,et al.  Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer. , 2005, Urologic oncology.

[44]  J. Bacik,et al.  Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  John D Boice,et al.  Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. , 2005, Journal of the National Cancer Institute.

[46]  J. Bacik,et al.  Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  L. Einhorn,et al.  Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  M. Koch,et al.  Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. , 2004, The Journal of urology.

[49]  R. Fimmers,et al.  Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. , 2004, The Journal of urology.

[50]  C. Bokemeyer,et al.  2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  C. Claussen,et al.  The role of [18F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of postchemotherapy residual masses in metastatic germ cell tumors—prospects for management , 2004, World Journal of Urology.

[52]  B. Leibovich,et al.  Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? , 2003, The Journal of urology.

[53]  M. Bains,et al.  The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours , 2003, BJU international.

[54]  PhD Harald J. Hoekstra MD,et al.  Non–Germ Cell Malignancy in Residual or Recurrent Mass After Chemotherapy for Nonseminomatous Testicular Germ Cell Tumor , 2003, Annals of Surgical Oncology.

[55]  P. Albers.  Surgery in testis cancer: laparoscopic and open techniques , 2002, Current opinion in urology.

[56]  L. Kavoussi,et al.  Laparoscopic retroperitoneal lymph node dissection after chemotherapy. , 2002, Urology.

[57]  S. Culine,et al.  Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  J. Habbema,et al.  Retroperitoneal metastases in testicular cancer: role of CT measurements of residual masses in decision making for resection after chemotherapy. , 2000, Radiology.

[59]  L. Einhorn,et al.  Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  R. Paterson,et al.  Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient? , 1998, British journal of urology.

[61]  P. Alken,et al.  Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors: indications and limitations. , 1996, The Journal of urology.

[62]  M. Burt,et al.  Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  J P Donohue,et al.  Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  D. Bajorin,et al.  Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors , 1994, Cancer.

[65]  T. Ulbright,et al.  Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  R. Motzer,et al.  Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. , 1992, The Journal of urology.

[67]  S. Fosså,et al.  Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  N. Geller,et al.  Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  S. Fosså,et al.  Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. , 1989, The Journal of urology.

[70]  U. Chaudhary,et al.  Long-Term Complications of Chemotherapy for Germ Cell Tumours , 2012, Drugs.

[71]  A. Horwich,et al.  2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  A. Horwich,et al.  Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  P. Albers,et al.  Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. , 2009, European urology.

[74]  S. Fosså,et al.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. , 2008, European urology.

[75]  J. Habbema,et al.  Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.